Vascular Therapies has raised $12.4 million from 29 investors as part of a $21.1 million round, according to a document filed last week with the SEC. The Cresskill, N.J.-based company is developing a sirolimus-eluting collagen implant for patients with end-stage renal disease. The bioresorbable drug-delivery system is designed to keep open a portal of entry […]
Tandem wins approval for insulin pump in Canada
Tandem Diabetes Care (NSDQ:TNDM) won a medical device license from Health Canada last week for its t:slim X2 insulin pump. The device integrates directly with Dexcom‘s (NSDQ:DXCM) G5 continuous glucose monitor and is the only system of its kind approved in Canada, according to the San Diego, Calif.-based company. Tandem said it plans to launch the […]
Canada clears Medtronic’s MiniMed 670G insulin pump
Medtronic‘s (NYSE:MDT) Canada subsidiary said today that it won a license from Health Canada for its MiniMed 670G insulin pump system. The insulin pump system is the first device in Canada that stabilizes glucose levels by automatically adjusting basal insulin delivery according to a user’s real-time needs, the medtech titan touted. Medtronic expects to launch […]
Genentech kicks off Phase III trial for eye implant
Roche‘s (OTC:RHHBY) Genentech reported this week that the company launched Phase III trials evaluating its Port drug-delivery implant in patients with wet age-related macular degeneration and the drug faricimab in patients with diabetic macular edema. The company’s Port device is a refillable eye implant designed to continuously release drugs over a period of several months. “Wet […]
Frequency completes enrollment in safety trial for hearing loss drug
Frequency Therapeutics said today that it finished enrolling participants in a single-dose safety trial for its FX-322 hearing loss drug candidate. The company’s drug candidate emerged as part of its Progenitor Cell Activation platform – the combination of small molecules are designed to activate progenitor cells and trigger the formation of new hair cells in […]
ivWatch inks development, commercialization deal with ICU Medical
ivWatch said today that it inked a long-term development and commercialization deal to integrate its continuous IV monitor into new medical devices and systems made by ICU Medical (NSDQ:ICUI). The deal paves the way for EHR interoperability, according to ivWatch, by connecting the two companies’ systems and enabling the exchange of data. “Our two companies can […]
Pari Pharma lands FDA nod for Lamira nebulizer
Pari Pharma said this week that its Lamira nebulizer won approval from the FDA to deliver Insmed’s Arikayce amikacin liposome inhalation suspension for the treatment of MAC lung disease. The company’s Lamira drug-device combination product is intended to be used as part of a combination antibacterial drug regimen for adult patients with limited or no […]
Researchers tout use of closed-loop insulin delivery system
At this year’s meeting of the European Association for the Study of Diabetes, researchers reported that use of a hybrid day-night closed-loop insulin delivery system is better than sensor-augmented pump therapy for blood sugar control in people with poorly controlled Type 1 diabetes. The JDRF-funded study included 44 men and 42 women with Type 1 […]
Medherant wins grant to support manufacturing program for transdermal drug-delivery patches
Medherant said today that it was awarded a Medicines Manufacturing Grant from Innovate UK to support the manufacturing of transdermal drug-delivery patches. The company plans to expand its pilot-scale GMP manufacturing program, which is designed to make patches formulated with its Tepi patch tech for clinical trials. Medherant touts its Tepi technology as enabling the […]
Kala Pharmaceuticals prices $62m public offering
Kala Pharmaceuticals (NSDQ:KALA) priced an underwritten public offering of 7,500,000 shares of common stock at $8.25 per share. The Waltham, Mass.-based company is expected to reel in nearly $62 million in proceeds from the offering. Kala Pharmaceuticals also gave underwriters a 30-day option to buy an additional 1,125,000 shares of common stock at $8.25 apiece. The […]
